搜尋結果
The Novavax COVID-19 vaccine, sold under the brand names Nuvaxovid and Covovax, among others, is a subunit COVID-19 vaccine developed by Novavax and the Coalition for Epidemic Preparedness Innovations (CEPI). Medical uses The Novavax COVID‑19 ...
- AU: B1
- Intramuscular
- Covovax, Nuvaxovid
- SARS-CoV-2
Novavax, Inc. is an American biotechnology company based in Gaithersburg, Maryland, that develops vaccines to counter serious infectious diseases. Prior to 2020, company scientists developed experimental vaccines for influenza and respiratory syncytial virus (RSV), as well as Ebola and other emerging infectious diseases.
- 1987; 36 years ago
- Gaithersburg, Maryland, U.S.
- 1,541 (2022)
- US$1.982 billion (2022)
Novavax Subunit/virus-like particle United States December 2021 A "recombinant nanoparticle vaccine" Covaxin Inactivated India January 2021 Valneva Inactivated France, Austria April 2022 Sanofi–GSK Subunit France, United Kingdom November 2022 Based on
The Novavax COVID-19 vaccine, sold under the brand names Nuvaxovid and Covovax, is a subunit COVID-19 vaccine candidate developed by Novavax and the Coalition for Epidemic Preparedness Innovations. Full (4) Australia Canada Japan South Korea
CoronaVac, also known as the Sinovac COVID-19 vaccine, is a whole inactivated virus COVID-19 vaccine developed by the Chinese company Sinovac Biotech. It was phase III clinically trialled in Brazil, Chile, Indonesia, the Philippines, and Turkey and relies on traditional technology similar to other inactivated-virus COVID-19 vaccines, such as the Sinopharm BIBP vaccine, another Chinese vaccine ...
- PiCoVacc
- SARS-CoV-2
- CoronaVac
- Inactivated
The Pfizer–BioNTech COVID-19 vaccine, sold under the brand name Comirnaty, [2] [32] is an mRNA-based COVID-19 vaccine developed by the German biotechnology company BioNTech. For its development, BioNTech collaborated with the American company Pfizer to carry out clinical trials, logistics, and manufacturing. [44] [45] It is authorized for use ...
The COVID-19 vaccination campaign in the United States is an ongoing mass immunization campaign for the COVID-19 pandemic in the United States. The Food and Drug Administration (FDA) first granted emergency use authorization to the Pfizer–BioNTech vaccine on December 10, 2020, [7] and mass vaccinations began four days later.
